Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

(2021) Leisha A Emens et al.   JNCI-Journal of the National Cancer Institute

Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis

(2021) Caroline Boman et al.   CANCER TREATMENT REVIEWS

The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.

(2021) Leisha A. Emens et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer

(2021) Hope S Rugo et al.   JNCI-Journal of the National Cancer Institute

Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma

(2020) Sebastian Lundgren et al.   INTERNATIONAL JOURNAL OF CANCER

Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC

(2020) Joe Yeong et al.   JOURNAL OF CLINICAL PATHOLOGY

Programmed Death Ligand‐1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease

(2020) Ioannis Zerdes et al.   Molecular Oncology

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies

(2020) E. S. Stovgaard et al.   BREAST CANCER RESEARCH AND TREATMENT

LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

(2020) D.W. Miles et al.   ANNALS OF ONCOLOGY

A multicentre analytical comparison study of inter‐reader and inter‐assay agreement of four programmed death‐ligand 1 (PD‐L1) immunohistochemistry assays for scoring in triple‐negative breast cancer

(2020) Aurelia Noske et al.   HISTOPATHOLOGY

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

(2020) Elizabeth A Mittendorf et al.   LANCET

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

(2020) Javier Cortes et al.   LANCET

10OComparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC)

(2019) M Scott et al.   ANNALS OF ONCOLOGY

HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.

(2019) Otto Metzger Filho et al.   JOURNAL OF CLINICAL ONCOLOGY

Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy

(2019) Chrétien et al.   Cancers

Prognostic implications of PD-L1 expression in breast cancer: systematic review and meta-analysis of immunohistochemistry and pooled analysis of transcriptomic data

(2019) Alexios Matikas et al.   CLINICAL CANCER RESEARCH

Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry

(2019) David Jonathan Duncan et al.   PLoS One

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

(2019) Steve Lu et al.   JAMA Oncology

Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response

(2019) Alexander Haragan et al.   LUNG CANCER

Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies

(2019) Nicola L. Lawson et al.   MODERN PATHOLOGY

STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer

(2019) Zerdes et al.   Cancers

Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer

(2018) Ming Li et al.   BMC CANCER

PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer

(2018) Xinyu Ren et al.   CANCER BIOLOGY & THERAPY

Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing

(2018) Charissa Kim et al.   CELL

Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients

(2018) Artur Mezheyeuski et al.   JOURNAL OF PATHOLOGY

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations

(2018) Ioannis Zerdes et al.   ONCOGENE

Immunological differences between primary and metastatic breast cancer

(2018) B Szekely et al.   ANNALS OF ONCOLOGY

Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer

(2018) Alexios Matikas et al.   OncoImmunology

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival

(2018) Marcelo Sobral-Leite et al.   OncoImmunology

Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases

(2018) Quirine F. Manson et al.   CLINICAL & EXPERIMENTAL METASTASIS

PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas

(2018) Dan Guo et al.   HUMAN PATHOLOGY

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer

(2018) Matthew P. Humphries et al.   Journal of Oncology

Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial

(2017) Siker Kimbung et al.   INTERNATIONAL JOURNAL OF CANCER

Diagnostic Utility of PD-L1 Expression in Lung Adenocarcinoma

(2017) Mohamad Mazen Gafeer et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer

(2017) Thomas Karn et al.   JAMA Oncology

Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies

(2016) Woo Young Sun et al.   Journal of Translational Medicine

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker

(2016) Lei Guo et al.   SpringerPlus

Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma

(2015) Ziming Du et al.   Oncotarget

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

(2014) K. A. Schalper et al.   CLINICAL CANCER RESEARCH